title: [Effect of CYP3A4*18B, CYP3A5*3 gene polymorphism on dosage and concentration of tacrolimus in renal transplant patients].
abstract: The effect of CYP3A4*18B and CYP3A5*3 on concentration/dosage x body surface area ratios (C/D'), adverse effects and acute rejection of tacrolimus in renal transplant patients were investigated. The CYP3A4*18B genotypes of 227 renal transplant patients were determined by PCR-RFLP method. The differences of C/D' ratios, adverse reactions and acute rejection were compared among all of the genotype groups treated with tacrolimus. The frequencies of CYP3A4*18 and CYP3A5*3 alleles in renal transplant patients were 30.8% and 74.2%, respectively. No significant association was found between the C/D's of tacrolimus and CYP3A4*18B genotypes when they were classified by two CYP3A5 genotypes (P > 0.05). While after the effects of CYP3A4*18B genotype were eliminated, the C/D' ratio of tacrolimus in patients with CYP3A5*1/*1 and *1/*3 genotype group was significantly lower than those with CYP3A5*3/*3 genotype groups (P < 0.01). There is no significant difference in adverse effects and acute rejection among different genotypes (P > 0.05).
authors.affiliation: Department of Pharmacy, Fuzhou General Hospital of Nanjing Military Region, Fuzhou 350025, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Zhu
authors.forename: Hong-Tao
authors.initials: HT
authors.lastname: Song
authors.forename: Qing-Hua
authors.initials: QH
authors.lastname: Wang
authors.forename: Wei-Zhen
authors.initials: WZ
authors.lastname: Wu
authors.forename: Shun-Liang
authors.initials: SL
authors.lastname: Yang
authors.forename: Jian-Ming
authors.initials: JM
authors.lastname: Tan
mesh_terms: D000328:Adult; D000483:Alleles; D051544:Cytochrome P-450 CYP3A / Q000235:genetics*; D004066:Digestive System Diseases / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D005260:Female; D005838:Genotype; D006084:Graft Rejection / Q000235:genetics; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012189:Retrospective Studies; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D016559:Tacrolimus